Founded in 2021 by Dr. Zhiqian Zhang - a Generation Z, Tidetron Bioworks Technology Co., Ltd. is one of the world’s first synthetic bio-manufacturing platforms to realize mass production of various substances. In just 10 months, we have been financed over $100 million and recognized as a new star of synthetic biology worldwide.
We adhere to the principle of "It’s growing" and is committed to synthetic biotechnology innovation to meet people's new requirements on medicine, food, cosmetics, safety. Now we have established a chain from R&D to production and built our unique Tidetron Altra platform-based strain library and component library. We have made absolute breakthroughs in mass production and universality. Our factory could provide customized production, with an annual production capacity exceeding 10,000 tons.
At present, there are more than 30 substances on sale, including peptides, erythritol, and bulk commodities. We also provide integrated enterprise-universities-researches solutions in skin care, food and beverage, household cleaning, biomedicine, etc.
We built a "quick response" system with its exclusive technology, which has broken the bottleneck in transforming and applying. Efficient mass production technology makes the traditional mode of production enter "environmental protection mutation", and the industrial chain realizes a green upgrade. In the trend of green life, Tidetron, which influences Environmental, Social and Governance (ESG) and end products in the industry, is turning synthetic biology into the fundamental force that changes traditional production and making more people achieve the carbon peaking and carbon neutrality goals in daily life.
TIDETRON’S CORE TEAM
Zhiqian Zhang currently pursues a Ph.D. degree of clinical medicine in School of Medicine, SYSU.
Zhiqian has visited Yale School of Medicine and engaged in research at South China Stem Cell Research Center, Zhongshan Ophthalmology Center and Cardiovascular Center of Yale University.
In 2016, he won the Gold Medal, the Best Therapeutics Project and the Best New Composite Part of iGEM.
He has been listed on the 2021 Forbes China "30 under 30". Zhiqian now takes in charge of overall management and R&D.
Xianzhi Wang once worked for IDG Capital, and engaged in investment in the consumption and technology industries for 5 years. He participated in the investment over ￥1 billion. He was responsible for the post-investment management of 8 invested enterprises.
He now takes in charge of corporate strategy, investment and financing, and accounting.
Kevin Zhang has over 20+ years of B2B chemical business leadership experience in Asia Pacific and Greater China in leading MNCs among DuPont, INVISTA, CRISTAL, and Ferro.
The first Chinese executive once drove the business in two global top tier TiO2 companies respectively with strong position in the global business steering team.
Kevin also has the soundtrack record for successful integration of business team for high performance after acquisition of Chinese local and MNC mills, Kevin holds the MBA degree from HKUST.
Dr. Yirui Wu received his Ph.D. degree in microbiology from the City University of HK. He has served as a research fellow of the National University of Singapore, professor at the Shantou University and visiting professor of the University of Technology Sydney.
He has made a series of innovative achievements in microbial metabolic engineering and biotransformation of high value-added bio-based products.
He has published more than 30 papers in international top journals , and presided over and participated in more than 10 talent projects.